Correlation of GP73 and cytokines before antiviral therapy in patients with chronic hepatitis B

doi:10.3877/cma.j.issn.1674-1358.2017.02.008

Abstract

Abstract:

Objective

To investigate the correlation of serum GP73 and cytokines in different therapeutic groups of patients with chronic hepatitis B before treated with interferon, and to analyze the role of GP73 in chronic hepatitis B.

Methods

Total of 113 patients with CHB were enrolled. Serum levels of GP73, TNF-α, IFN-γ, IL-2, IL-10 and IL-12 were detected by enzyme-linked immunosorbent assay before patients treated with IFN-α antiviral therapy. The correlations between serum GP73 and cytokines were analyzed by Pearson’s correlations method.

Results

The concentrations of serum GP73, IL-2, IL-12, TNF-α and IFN-γ in patients with complete response to IFN treatment were significantly higher than those in patients with partial response (all P < 0.05). The concentrations of serum IL-2, TNF-α and IFN-γ in patients with non-response to IFN treatment were also significantly higher than those in patients with partial response (all P < 0.05). However, there were no significant differences between patients with complete response and non-response except for IL-2 and IL-10 (P > 0.05). Moreover, there were significant positive correlations between serum GP73 and cytokines of TNF-α (r = 0.8045, P < 0.001), IL-2 (r = 0.5693, P < 0.001) and IL-12 (r = 0.499, P = 0.001) in patients with complete response to IFN treatment. And in patients with partial response, the correlation between serum GP73 and IL-12 (r = 0.4248, P = 0.0107) was significant, however, the correlation between serum GP73 and the other cytokines were not significant. The level of GP73 and cytokines in patients with non-response to IFN treatment were with no correlation.

Conclusions

GP73 in patients with CHB may participate in immune regulation.

Key words: Golgi protein 73, Cytokines, Interleukin 12

Meijuan Wei, Xiaoman Zhang, Zhengju Xu, Zihong Xiao, Chunyu Zhang, Caiting He. Correlation of GP73 and cytokines before antiviral therapy in patients with chronic hepatitis B[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2017, 11(02): 141-145.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-1358.2017.02.008

https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/Y2017/V11/I02/141

Figures/Tables 6

References 20

1	Kladney, RD, Bulla GA, Guo L, et al. GP73, a novel Golgi-localized protein upregulated by viral infection[J]. Gene,2000,249(1-2):53-65.
2	张勤，续薇. 高尔基体蛋白73与肝脏疾病关系的研究进展[J]. 国际检验医学杂志,2014,35(15): 2058-2060.
3	Kladney RD, Cui X, Bulla GA, et al. Expression of GP73, a resident Golgi membrane protein, in viral and nonviral liver disease[J]. Hepatology,2002,35(6):1431-1440.
4	许正锯，潘兴南，魏开鹏, 等. 血清高尔基体蛋白73与慢性乙型肝炎病毒感染者肝脏炎症损伤的相关性[J/CD]. 中华实验和临床感染病杂志(电子版),2014,8(5):598-604.
5	Xu Z, Liu L, Pan X, et al. Serum Golgi protein 73 (GP73) is a diagnostic and prognostic marker of chronic HBV liver disease[J]. Medicine(Baltimore),2015,94(12):e659.
6	Liang H, Block TM, Wang M, et al., Interleukin-6 and oncostatin M are elevated in liver disease in conjunction with candidate hepatocellular carcinoma biomarker GP73[J]. Cancer Biomark,2012,11(4):161-171.
7	中华医学会肝病学分会，中华医学会感染病学分会. 慢性乙型肝炎防治指南(2010年版)[J/CD]. 中国肝脏病杂志(电子版),2011,3(1):40-56.
8	吴群，刘小兵. 干扰素α-1b治疗慢性乙肝疗效10年随访[J]. 医学信息,2013,27(14):197-198.
9	Sadler AJ, Williams BR. Interferon-inducible antiviral effectors[J]. Nat Rev Immunol,2008,8(7):559-568.
10	Pham NL, Badovinac VP, Harty JT. Differential role of "ignal 3" inflammatory cytokines in regulating CD8 T cell expansion and differentiation in vivo[J]. Front Immunol,2011,2:4.
11	Crouse J, Kalinke U, Oxenius A. Regulation of antiviral T cell responses by type I interferons[J]. Nat Rev Immunol,2015,15(4):231-242.
12	Ramos HJ, Davis AM, George TC, et al. IFN-alpha is not sufficient to drive Th1 development due to lack of stable T-bet expression[J]. J Immunol,2007,179(6):3792-3803.
13	Isorce N, Lucifora J, Zoulim F, et al. Immune-modulators to combat hepatitis B virus infection: From IFN-α to novel investigational immunotherapeutic strategies[J]. Antiviral Res,2015,122:69-81.
14	Tangkijvanich P, Komolmit P, Mahachai V, et al. Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B[J]. J Clin Virol,2009,46(2):117-123.
15	Hansen BE, Buster EH, Steyerberg EW, et al.Prediction of the response to peg-interferon-alfa in patients with HBeAg positive chronic hepatitis B using decline of HBV DNA during treatment[J]. J Med Virol,2010,82(7):1135-1142.
16	占国清，谭华炳，谢杏榕, 等. α干扰素治疗HBeAg阳性慢性乙型肝炎疗效的预测指标[J]. 胃肠病学和肝病学杂志,2011,20(7):663-665.
17	Iftikhar R, Kladney RD, Havlioglu N, et al. Disease- and cell-specific expression of GP73 in human liver disease[J]. Am J Gastroenterol,2004,99(6):1087-1095.
18	Hu L, Yao W, Wang F, et al. GP73 is upregulated by hepatitis C virus (HCV) infection and enhances HCV secretion[J]. PLoS One,2014,9(3):e90553.
19	冯志刚，岑晓红，云俊木, 等. GP73在酒精性肝病中的临床意义[J]. 国际检验医学杂志,2015,36(15):2214-2215.
20	Wang F, Long Q, Gong Y, et al. Epithelium-Specific ETS (ESE)-1 upregulated GP73 expression in hepatocellular carcinoma cells[J]. Cell Biosci,2014,4(1):76-86.

组别	例数	年龄（±s，岁）	男性[例（%）]	GP73（±s，ng/ml）	IL-2（±s，pg/ml）	IL-10（±s，pg/ml）
对照组	50	27.85±4.58	40（80.00）	40.38±17.69	15.19±4.15	10.03±2.51
病毒学应答组	39	29.69±8.22	33（84.62）	130.6±58.35	106.90±32.55	27.10±7.59
部分病毒学应答组	35	28.00±2.65	28（80.00）	98.17±40.36	56.16±13.97	23.92±6.33
无应答组	39	26.69±6.50	30（76.92）	124.40±66.60	104.80±95.99	26.20±13.94
^a统计量		q = 1.623	χ² = 0.27	H = 2.525	H = 6.249	H = 1.628
^aP值		0.487	0.602	0.012	< 0.001	0.104
^b统计量		q = 1.254	χ² = 0.7429	H = 1.808	H = 2.877	H = 0.715
^bP值		0.65	0.743	0.071	0.004	0.475
^c统计量		q = 2.958	χ² = 0.1031	H = 0.737	H = 3.467	H = 2.408
^cP值		0.296	0.748	0.461	0.001	0.016
组别	例数	IL-12（±s，ng/ml）	TNF-α（±s，pg/ml）	IFN-γ（±s，pg/ml）	HBV DNA（±s，log₁₀拷贝/ml）	ALT（±s，IU/L）
对照组	50	1.35±0.82	5.27±1.03	18.65±4.01	< 2.69	21.43±8.15
病毒学应答组	39	7.92±2.12	66.08±8.51	45.30±10.12	6.30±0.87	520.00±323.6
部分病毒学应答组	35	6.27±1.44	59.64±3.86	34.77±5.85	6.72±0.89	674.80±550.4
无应答组	39	8.31±6.11	71.22±29.04	45.51±24.29	6.64±0.84	394.50±325.6
^a统计量		H = 2.983	H = 3.373	H = 4.76	q = 2.965	H = 0.973
^aP值		0.003	0.001	< 0.001	0.095	0.771
^b统计量		H = 1.010	H =-2.217	H =-2.771	q = 0.530	H = 3.087
^bP值		0.313	0.027	0.006	0.926	0.079
^c统计量		H = 2.029	H = 1.188	H = 2.045	q = 2.504	H = 2.173
^cP值		0.042	0.235	0.041	0.184	0.278

组别	例数	年龄（±s，岁）	男性[例（%）]	GP73（±s，ng/ml）	IL-2（±s，pg/ml）	IL-10（±s，pg/ml）
对照组	50	27.85±4.58	40（80.00）	40.38±17.69	15.19±4.15	10.03±2.51
病毒学应答组	39	29.69±8.22	33（84.62）	130.6±58.35	106.90±32.55	27.10±7.59
部分病毒学应答组	35	28.00±2.65	28（80.00）	98.17±40.36	56.16±13.97	23.92±6.33
无应答组	39	26.69±6.50	30（76.92）	124.40±66.60	104.80±95.99	26.20±13.94
^a统计量		q = 1.623	χ² = 0.27	H = 2.525	H = 6.249	H = 1.628
^aP值		0.487	0.602	0.012	< 0.001	0.104
^b统计量		q = 1.254	χ² = 0.7429	H = 1.808	H = 2.877	H = 0.715
^bP值		0.65	0.743	0.071	0.004	0.475
^c统计量		q = 2.958	χ² = 0.1031	H = 0.737	H = 3.467	H = 2.408
^cP值		0.296	0.748	0.461	0.001	0.016
组别	例数	IL-12（±s，ng/ml）	TNF-α（±s，pg/ml）	IFN-γ（±s，pg/ml）	HBV DNA（±s，log₁₀拷贝/ml）	ALT（±s，IU/L）
对照组	50	1.35±0.82	5.27±1.03	18.65±4.01	< 2.69	21.43±8.15
病毒学应答组	39	7.92±2.12	66.08±8.51	45.30±10.12	6.30±0.87	520.00±323.6
部分病毒学应答组	35	6.27±1.44	59.64±3.86	34.77±5.85	6.72±0.89	674.80±550.4
无应答组	39	8.31±6.11	71.22±29.04	45.51±24.29	6.64±0.84	394.50±325.6
^a统计量		H = 2.983	H = 3.373	H = 4.76	q = 2.965	H = 0.973
^aP值		0.003	0.001	< 0.001	0.095	0.771
^b统计量		H = 1.010	H =-2.217	H =-2.771	q = 0.530	H = 3.087
^bP值		0.313	0.027	0.006	0.926	0.079
^c统计量		H = 2.029	H = 1.188	H = 2.045	q = 2.504	H = 2.173
^cP值		0.042	0.235	0.041	0.184	0.278

组别	例数	GP73（ng/ml）	IL-2（pg/ml）	r值	P值
病毒学应答组	39	130.6±58.35	106.9±32.55	0.5693	< 0.0010
部分病毒学应答组	35	98.17±40.36	56.16±13.97	0.0062	0.9719
无应答组	39	124.40±66.60	104.80±95.99	0.0270	0.8703

组别	例数	GP73（ng/ml）	IL-2（pg/ml）	r值	P值
病毒学应答组	39	130.6±58.35	106.9±32.55	0.5693	< 0.0010
部分病毒学应答组	35	98.17±40.36	56.16±13.97	0.0062	0.9719
无应答组	39	124.40±66.60	104.80±95.99	0.0270	0.8703

组别	例数	GP73（ng/ml）	IL-10（pg/ml）	r值	P值
病毒学应答组	39	130.6±58.35	27.10±7.59	0.2352	0.1500
部分病毒学应答组	35	98.17±40.36	23.92±6.33	-0.0266	0.8794
无应答组	39	124.40±66.60	26.20±13.94	-0.0619	0.7079

Please choose a citation manager

Content to export